391 related articles for article (PubMed ID: 22171512)
1. [Safety of medicinal nanoproducts: new areas of toxicological research].
Grudziński IP
Rocz Panstw Zakl Hig; 2011; 62(3):239-46. PubMed ID: 22171512
[TBL] [Abstract][Full Text] [Related]
2. Research strategies for safety evaluation of nanomaterials, part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs.
Holsapple MP; Farland WH; Landry TD; Monteiro-Riviere NA; Carter JM; Walker NJ; Thomas KV
Toxicol Sci; 2005 Nov; 88(1):12-7. PubMed ID: 16120754
[TBL] [Abstract][Full Text] [Related]
3. [Modern toxicology of magnetic nanomaterials].
Cywińska MA; Grudziński IP
Rocz Panstw Zakl Hig; 2012; 63(3):247-56. PubMed ID: 23173329
[TBL] [Abstract][Full Text] [Related]
4. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles.
Tsuji JS; Maynard AD; Howard PC; James JT; Lam CW; Warheit DB; Santamaria AB
Toxicol Sci; 2006 Jan; 89(1):42-50. PubMed ID: 16177233
[TBL] [Abstract][Full Text] [Related]
5. Nanomaterial health effects--part 1: background and current knowledge.
Powell MC; Kanarek MS
WMJ; 2006 Mar; 105(2):16-20. PubMed ID: 16628969
[TBL] [Abstract][Full Text] [Related]
6. Nanomaterial health effects part 3: conclusion--hazardous issues and the precautionary principle.
Kanarek MS
WMJ; 2007 Feb; 106(1):16-9. PubMed ID: 17393752
[TBL] [Abstract][Full Text] [Related]
7. Nanomaterial health effects--Part 2: Uncertainties and recommendations for the future.
Powell MC; Kanarek MS
WMJ; 2006 May; 105(3):18-23. PubMed ID: 16749320
[TBL] [Abstract][Full Text] [Related]
8. Toxicological aspects for nanomaterial in humans.
Dusinska M; Magdolenova Z; Fjellsbø LM
Methods Mol Biol; 2013; 948():1-12. PubMed ID: 23070759
[TBL] [Abstract][Full Text] [Related]
9. Nanomaterials in the environment: from materials to high-throughput screening to organisms.
Thomas CR; George S; Horst AM; Ji Z; Miller RJ; Peralta-Videa JR; Xia T; Pokhrel S; Mädler L; Gardea-Torresdey JL; Holden PA; Keller AA; Lenihan HS; Nel AE; Zink JI
ACS Nano; 2011 Jan; 5(1):13-20. PubMed ID: 21261306
[TBL] [Abstract][Full Text] [Related]
10. Research strategies for safety evaluation of nanomaterials, Part I: evaluating the human health implications of exposure to nanoscale materials.
Thomas K; Sayre P
Toxicol Sci; 2005 Oct; 87(2):316-21. PubMed ID: 16049265
[TBL] [Abstract][Full Text] [Related]
11. The changing face of nanomaterials: Risk assessment challenges along the value chain.
Mattsson MO; Simkó M
Regul Toxicol Pharmacol; 2017 Mar; 84():105-115. PubMed ID: 27998719
[TBL] [Abstract][Full Text] [Related]
12. The importance of life cycle concepts for the development of safe nanoproducts.
Som C; Berges M; Chaudhry Q; Dusinska M; Fernandes TF; Olsen SI; Nowack B
Toxicology; 2010 Mar; 269(2-3):160-9. PubMed ID: 20025922
[TBL] [Abstract][Full Text] [Related]
13. [Research strategy for evaluation methods of the manufactured nanomaterials in NIHS and importance of the chronic health effects studies].
Hirose A; Nishimura T; Kanno J
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2009; (127):15-25. PubMed ID: 20306702
[TBL] [Abstract][Full Text] [Related]
14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
15. Grouping of nanomaterials to read-across hazard endpoints: from data collection to assessment of the grouping hypothesis by application of chemoinformatic techniques.
Lamon L; Asturiol D; Richarz A; Joossens E; Graepel R; Aschberger K; Worth A
Part Fibre Toxicol; 2018 Sep; 15(1):37. PubMed ID: 30249272
[TBL] [Abstract][Full Text] [Related]
16. Manufactured nanomaterials: categorization and approaches to hazard assessment.
Gebel T; Foth H; Damm G; Freyberger A; Kramer PJ; Lilienblum W; Röhl C; Schupp T; Weiss C; Wollin KM; Hengstler JG
Arch Toxicol; 2014 Dec; 88(12):2191-211. PubMed ID: 25326817
[TBL] [Abstract][Full Text] [Related]
17. Nanotoxicity: the growing need for in vivo study.
Fischer HC; Chan WC
Curr Opin Biotechnol; 2007 Dec; 18(6):565-71. PubMed ID: 18160274
[TBL] [Abstract][Full Text] [Related]
18. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward.
Lai DY
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2012; 4(1):1-15. PubMed ID: 21965171
[TBL] [Abstract][Full Text] [Related]
19. Health effects classification and its role in the derivation of minimal risk levels: renal effects.
Chou CH; Pohl HR
Regul Toxicol Pharmacol; 2005 Jul; 42(2):202-8. PubMed ID: 15921839
[TBL] [Abstract][Full Text] [Related]
20. Development of in vitro systems for nanotoxicology: methodological considerations.
Stone V; Johnston H; Schins RP
Crit Rev Toxicol; 2009; 39(7):613-26. PubMed ID: 19650720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
